The consumption of non-steroid anti-inflammatory and antirheumatic medicines in Canada is projected to decrease moderately over the next five years. From 2024 to 2028, there is a consistent year-on-year decline in defined daily dosage per thousand persons per day, totaling roughly a 0.3-point decrease annually. Compared to 2023, there is a clear downward adjustment. Over the forecast period, the compound annual growth rate (CAGR) shows a consistent negative slope, indicating a trend of decreasing usage of these medicines.
Future trends to watch for include potential shifts in medical care practices, such as increased use of alternative treatments, the impact of new drug developments, and shifting demographics. These could affect the demand for non-steroid anti-inflammatory drugs and antirheumatic medications in Canada.
